Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

[1]  Bing-he Xu,et al.  Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2009, The Cochrane database of systematic reviews.

[3]  M. Dimopoulos,et al.  A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer , 2009, Breast Cancer Research and Treatment.

[4]  R. Pazdur,et al.  Ixabepilone in Combination with Capecitabine and as Monotherapy for Treatment of Advanced Breast Cancer Refractory to Previous Chemotherapies Report from the Fda , 2022 .

[5]  J. Gralow,et al.  Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. , 2008, Clinical breast cancer.

[6]  R. Ivker,et al.  Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14. , 2008, Journal of palliative medicine.

[7]  Tomasz Burzykowski,et al.  Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Esteva,et al.  Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. , 2008, Seminars in oncology.

[10]  F. Lee,et al.  Preclinical discovery of ixabepilone, a highly active antineoplastic agent , 2008, Cancer Chemotherapy and Pharmacology.

[11]  E. Thomas.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Lee,et al.  Preclinical efficacy spectrum and pharmacokinetics of ixabepilone , 2008, Cancer Chemotherapy and Pharmacology.

[13]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[14]  W. Gradishar,et al.  Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  A. Seidman,et al.  Point: combination versus single-agent chemotherapy: the argument for sequential single agents. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  E. Perez,et al.  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Baselga,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Sparano,et al.  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Ruíz,et al.  Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. , 2007, The Lancet. Oncology.

[20]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[21]  K. Gelmon,et al.  The role of capecitabine in first-line treatment for patients with metastatic breast cancer. , 2006, The oncologist.

[22]  J. O’Shaughnessy.  Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.

[23]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Thaler,et al.  Symptom prevalence, characteristics and distress in a cancer population , 1994, Quality of Life Research.

[25]  F. Lee,et al.  BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Bonneterre,et al.  Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Armitage,et al.  Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.

[28]  M. Tamburini,et al.  Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. , 1996, European journal of cancer.

[29]  G. Brufman,et al.  Prognostic factors affecting treatment results with combination chemotherapy in metastatic breast cancer. , 1986, Anticancer research.

[30]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.